Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study by Rawshani, Araz et al.
  
 
 
 
 
Rawshani, A., Sattar, N., Franzén, S., Rawshani, A., Hattersley, A. T., Svensson, A.-M., 
Eliasson, B. and Gudbjörnsdottir, S. (2018) Excess mortality and cardiovascular disease 
in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-
based cohort study. Lancet, 392(10146), pp. 477-486. 
 
   
There may be differences between this version and the published version. You are 
advised to consult the publisher’s version if you wish to cite from it. 
 
 
 
http://eprints.gla.ac.uk/168325/  
      
 
 
 
 
 
 
Deposited on: 17 February 2020 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk  
  
Excess mortality and cardiovascular disease in type 1 1 
diabetes in relation to age at onset: a nationwide 2 
study of 27,195 young adults with diabetes 3 
 4 
Araz Rawshani1*, Professor Naveed Sattar2*, Stefan Franzén3, Aidin Rawshani4, 5 
Professor Andrew T Hattersley, Ann-Marie Svensson3, Professor Björn Eliasson5, 6 
Professor Soffia Gudbjörnsdottir2,3  7 
 8 
1Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 9 
Gothenburg, Sweden 10 
2Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK 11 
3The Swedish National Diabetes Register, Västra Götalandsregionen, Gothenburg, Sweden 12 
4The Sahlgrenska University Hospital, Gothenburg, Sweden 13 
Institute of Biomedical & Clinical Science, University of Exeter Medical School, Exeter, UK 14 
5Department of Internal Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, 15 
Sweden 16 
 17 
* Joint first authors 18 
 19 
Corresponding authors: 20 
Araz.rawshani@gu.se 21 
Naveed.Sattar@glasgow.ac.uk 22 
 23 
Manuscript word count: 3520 words 24 
Abstract word count: 258 words 25 
26 
Evidence before this study 27 
People with type 1 diabetes are at 2- to 5-fold increased risk of death and 3- to 7-fold increased risk 28 
of coronary heart disease. Several risk factors, notably glycemic control, affect survival in type 1 29 
diabetes. The importance of age at disease onset, however, remains weakly studied. Guidelines do 30 
not articulate any specific recommendations in relation to age at disease onset, only duration. We 31 
did a systematic search in PubMed for articles published between Jan 1, 1960, and April 15, 2018. 32 
Our search terms included “type 1 diabetes”, “age at diagnosis”, “age at disease onset”, “childhood 33 
onset”, “late onset”, “debut age”, “mortality”, “cardiovascular disease”, “coronary artery disease”, 34 
“myocardial infarction”. We searched articles by title and abstract to identify relevant studies. 35 
Studies were also sought within reference lists of eligible studies. We considered studies that 36 
evaluated association between age at onset/diagnosis of type 1 diabetes and cardiovascular disease 37 
and survival. Studies using diabetes free controls as comparator were of primary interest, as such 38 
studies addresses the excess risk conferred by diabetes. 39 
 40 
Added value of this study 41 
By studying 27,195 individuals with type 1 diabetes and 135,178 matched controls, we demonstrate 42 
a ubiquitous inverse association between age at diagnosis and risk of mortality and cardiovascular 43 
disease, independent of diabetes duration. Patients with type 1 diabetes with disease onset before 44 
10 years of age experienced a 30-fold increased risk of CHD and AMI. Women with onset of type 1 45 
diabetes before 10 years of age displayed a 60- and 90-fold increased risk of CHD and AMI, 46 
respectively. The difference in risk levels between those with onset at age 0–10 years and 25–30 47 
years was up to 5-fold (AMI and CHD). Although absolute risks were low in this young cohort, 48 
developing T1D before 10 years of age resulted in a loss of 17.7 and 14.2 life years for women and 49 
men, respectively, whereas years of life lost were around 9-10 years with later age at diagnosis.  50 
 51 
Implications of all the available evidence 52 
Age at disease onset appears an important determinant of survival and, in particular of, 53 
cardiovascular disease in type 1 diabetes. These findings suggest that more patients with earlier 54 
onset type 1 diabetes be offered cardioprotective medications (statins, BP medications) sooner than 55 
currently practiced. A greater effort towards improved glycaemia control in such individual would 56 
also be beneficial.  57 
 58 
 59 
  60 
Abstract 61 
Background 62 
We compared individuals with type 1 diabetes (T1D) to matched controls in order to 63 
examine how age at diagnosis of T1D relates to excess mortality and cardiovascular 64 
(CV) risk. 65 
 66 
Methods 67 
We studied 27,195 persons with T1D in the Swedish National Diabetes Registry, and 68 
135,178 matched controls from the general population. Using Cox regression, and 69 
with adjustment for diabetes duration, we estimated excess risk of all-cause 70 
mortality, CV mortality, non-CV mortality, acute myocardial infarction (AMI), stroke, 71 
CVD (AMI and stroke), coronary heart disease (CHD), heart failure (HF) and atrial 72 
fibrillation (AF). Individuals with T1D were categorized into five groups, according to 73 
age at diagnosis: 0–9, 10–14, 15–19, 20–24 and 25–30 years.  74 
 75 
Findings 76 
A total of 27,195 persons with T1D and 135,178 controls were included; 924 persons 77 
with T1D and 1,405 controls died during follow-up, of which median was 10 years. 78 
Patients who developed T1D at 0–10 years of age displayed hazard ratios (95% CI) of 79 
4.11 (3.24–5.22) for death, 7.38 (3.65–14.94) for CV death, 11.44 (7.95–16.44) for 80 
CVD, 30.50 (19.98–46.57) for CHD, 30.95 (17.59–54.45) for AMI, 6.45 (4.04–10.31) for 81 
stroke, 12.90 (7.30–22.51) for HF and 1.17 (0.62–2.20) for AF. Corresponding figures 82 
for those who developed T1D in the age-range 26–30 were 2.83 (2.38–3.37) for 83 
death, 3.64 (2.34–5.66) for CV death, 3.85 (3.05–4.87) for CVD, 6.08 (4.71–7.84) for 84 
CHD, 5.77 (4.08–8.16) for AMI, 3.22 (2.35–4.42) for stroke and 5.07 (3.55–7.22) for 85 
HF; hence excess risk differed up to 5-fold across the diagnosis age. The highest 86 
overall incidence rate, noted for all-cause mortality, was 1.9 (95% CI 1.71 to 2.11) per 87 
100.000 person-years for patients with T1D. Developing T1D before 10 years of age 88 
resulted in a loss of 17.7 and 14.2 life years for women and men, respectively, 89 
whereas years lost were 10.1 and 9.4 in those diagnosed between 26-30 years of age. 90 
 91 
Interpretation 92 
Age at onset of type 1 diabetes is an important determinant of survival, as well as all 93 
cardiovascular outcomes, with highest excess risk in females. Greater focus on 94 
cardioprotection maybe warranted in those with early onset T1D. 95 
 96 
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Introduction 99 
Type 1 diabetes is the second most common chronic disease of childhood, although 100 
the disorder may develop throughout the life span.1 Remarkable improvements in 101 
management and survival has been observed during the past century. A recent study 102 
demonstrated that the relative risk of death declined by 29% over a 10-year period. 103 
Yet, mortality in type 1 diabetes is still increased two- to eightfold,2,3 which is 104 
reflected by a loss of life expectancy at age 20 years of approximately 12 years.4 105 
Cardiovascular disease is the main driver of morbidity and mortality in people with 106 
type 1 diabetes. Guidelines therefore recommend aggressive management of 107 
cardiovascular risk factors in type 1 diabetes, especially once beyond 40 years of age 108 
or with evidence of microvascular complications.5 Yet, guidelines are not well 109 
adhered to in type 1 diabetes and even with risk factors at target, people with type 1 110 
diabetes are at elevated risk of mortality and cardiovascular disease.6 No current 111 
guideline considers age of onset as an important risk stratifier. 112 
 113 
Age at diagnosis may be important in type 1 diabetes. It may carry information on–114 
and thus act as a proxy for–several important factors, such as total glycemic load, 115 
varying autoimmune mechanisms, age-related variations in clinical care, differences 116 
in ability to cope with the disease etc. Accordingly, recent studies have demonstrated 117 
that age at diagnosis can contribute to identifying subtypes of type 2 diabetes in 118 
adults,7 as well as predict risk factor trajectories.8 Furthermore, other evidence 119 
supports younger onset type 2 diabetes being more harmful than diabetes diagnosed 120 
in later life.8,9 121 
 122 
By contrast, such data in type 1 diabetes are less evident.10-14 No study has examined 123 
how age at diagnosis relates to excess risk of death and cardiovascular outcomes, 124 
while accounting for duration of diabetes, and using such granular age categories. We 125 
studied 27,195 individuals with T1D and 135,178 matched controls to answer this 126 
research question. 127 
 128 
Methods 129 
Data sources and study population 130 
The Swedish National Diabetes Register (NDR),2,6,15 includes longitudinal data 131 
regarding risk factors, complications, treatment and management for virtually all 132 
individuals with type 1 diabetes aged 18 years and older. Virtually all Swedes ≥18 133 
years of age with type 1 diabetes are enrolled in the registry. Type 1 diabetes is 134 
defined for the NDR on the basis of epidemiological data: treatment only with insulin 135 
and a diagnosis at ≤30 years of age, which has been validated as accurate in 97% of 136 
cases. Validation was done by comparing the concordance between the 137 
epidemiological classification and the physician’s classification of diabetes type.16,17 138 
We included patients with at least 1 registration between January 1, 1998, and 139 
December 31, 2012. For the baseline (i.e the first registration in the NDR) each 140 
patient was matched for age, sex, and county with 5 controls (without diabetes 141 
mellitus) randomly selected from the Swedish population, as previously done.2,15,18 142 
Matching on county aimed at reducing geographical differences in characteristics.    143 
We excluded patients with type 1 diabetes, along with their controls, if the former 144 
had severe congenital disorders or syndromes that may bias the association between 145 
diabetes and outcomes. A complete list of these disorders is provided at the end of 146 
the supplementary appendix. If any individual in the matched set (consisting of 1 147 
individual with type 1 diabetes and 5 matched controls) had such conditions, the 148 
entire matched set was excluded. This led to exclusion of 0.6% of the originally 149 
eligible individuals. We also excluded individuals with inconsistent vital data (i.e the 150 
registration in the NDR was dated after time of death), which resulted in exclusion of 151 
255 patients with type 1 diabetes, along with their controls. Finally, we excluded 152 
individuals with more than 20 years duration of diabetes, the reason for which is 153 
explained below. Finally, 27,195 persons with type 1 diabetes and 135,178 matched 154 
controls were studied. Supplementary Tables 1 and 2 presents the number of 155 
individuals excluded due to congenital disorders and inconsistent vital data. 156 
 157 
Covariates, coexisting conditions and causes of death 158 
Information on socioeconomic data, coexisting conditions, dates and causes of death 159 
was retrieved by linking data to Statistics Sweden, the Swedish Inpatient Registry and 160 
the Cause of Death Register, respectively. Data linkage is seamless since all Swedish 161 
citizens are assigned to a personal identification number which is used in these 162 
registries. 163 
 164 
Statistics Sweden includes information regarding annual income, country of birth, 165 
marital status and education. The Inpatient Register includes all hospital admissions 166 
since 1987. Primary and secondary discharge diagnoses are coded according to the 167 
International Classification of Diseases (ICD). We assessed ICD-9 and ICD-10 codes to 168 
define the following coexisting conditions: coronary heart disease: 410-414 (ICD-9), 169 
I20-I25 (ICD-10); acute myocardial infarction: 410 (ICD-9), I21 (ICD-10); stroke: 431-170 
434, 436 (ICD-9), I61-I64 (ICD-10); hospitalization for heart failure: 428 (ICD-9), I50 171 
(ICD-10); atrial fibrillation: 427D (ICD-9), I48 (ICD-10); cancer: 140-208 (ID-9), C00-C97 172 
(ICD-10). For each outcome, only the first recorded event in the Inpatient Register 173 
was assessed. The validity and reliability of these diagnoses in the Inpatient Register 174 
has been examined in detail.19 175 
 176 
Outcomes and exposures 177 
We estimated the excess risk of all-cause mortality, cardiovascular (CV) mortality, 178 
non-cardiovascular mortality, acute myocardial infarction (AMI), stroke, CVD 179 
(composite of AMI and stroke), coronary heart disease (CHD), heart failure (HF) and 180 
atrial fibrillation (AFib). Individuals with type 1 diabetes were categorized into five 181 
groups, according to age at diagnosis: 0 to 10 years, 11 to 15 years, 16 to 20 years, 21 182 
to 25 years and 26 to 30 years. 183 
 184 
For each matched set (the patient with T1D and the matched controls), follow-up 185 
started on the date of the patient’s first registration in the NDR, and ended on date of 186 
event, death, emigration or end of follow-up (2014-12-31). 187 
 188 
Statistical methods 189 
Cox regression was used to study the association between age at diagnosis of 190 
diabetes and risk of the outcomes, compared with controls. Age was used as the 191 
underlying time-scale, allowing the baseline hazard to capture the increase in hazard 192 
due to aging. For individuals with type 1 diabetes, we centralized duration around its 193 
grand mean. Controls were modelled as individuals not yet diagnosed with diabetes, 194 
meaning that their duration of diabetes was set to zero; this allows us to account for 195 
duration without assigning an effect of duration to controls. The resulting hazard 196 
ratios represent the hazard ratio for each group after the average duration of 197 
diabetes, which was 13 years. In order to compute reliable estimates, we had to 198 
exclude patients with duration above 20 years. Limiting duration to 20 years allowed 199 
for computation of simple models, without the need for relaxing assumptions of 200 
linearity in duration and it also yielded the best overlap in distribution of duration 201 
between the diabetes groups. Moreover, limiting duration to 20 years also allows us 202 
to study a more contemporary cohort, which better reflects modern diabetes 203 
management. 204 
In all models, we adjusted for age (using it as time scale), sex, marital status, income, 205 
educational level, region of birth, duration of diabetes, previous histories of AMI, 206 
stroke, CVD, CHD, atrial fibrillation and heart failure. 207 
This was done in the entire cohort (i.e including people with >20 years duration of 208 
diabetes). The life years lost was estimated as the difference between the predicted 209 
conditional median survival post 18 years of age in the 0-10 years and 10-15 years 210 
group and post the upper age interval for the other groups. The predicted conditional 211 
survival functions were derived from a Cox regression model with T1DM vs controls 212 
as the only independent variable. Age was used as the time scale, with left censoring 213 
at age of inclusion. The conditional median survival was estimated from the upper 214 
limit of each age interval. 215 
The ethics committee of the University of Gothenburg, Sweden, approved the study. 216 
All patients with diabetes have provided informed consent before inclusion in the 217 
cohort. The funder had no role in any part of the study. 218 
 219 
Results 220 
A total of 27,195 persons with type 1 diabetes and 135,178 controls were included. 221 
Median follow-up was 10 years; 924 patients with type 1 diabetes and 1,405 controls 222 
died during follow-up. Follow-up time and number of deaths in each age category is 223 
presented in Supplementary Tables 3 and 4. 224 
 225 
Baseline characteristics 226 
 227 
Patients vs. controls 228 
Mean age among patients with T1D and controls was roughly 29 years and 56% were 229 
males (Table 1). There were only small differences in educational attainment and 230 
marital status between controls and patients. Controls earned 4700 SEK more per 231 
year (approximately 550 USD or 405 GBP). All coexisting conditions, with the 232 
exception of atrial fibrillation, were more common in patients with diabetes. 233 
Coronary artery disease at baseline was 9 times as common in patients with type 1 234 
diabetes. 235 
 236 
Patients with diabetes 237 
Mean ages in the five age-groups were 23.5, 25.7, 27.6, 32.2 and 37.9 years (Table 2). 238 
HbA1c values were higher in patients with younger age at onset. Use of 239 
antihypertensives and statins were lowest in those with low age at onset of type 1 240 
diabetes. Blood pressure, triglycerides, BMI, LDL cholesterol and prevalence of 241 
smoking increased with age at diagnosis. There were only small differences in 242 
physical activity and prevalence of micro- and macroalbuminuria. 243 
 244 
Absolute risk estimates 245 
Supplementary Tables 5 and 6 present incidence rates for all outcomes. Incidence 246 
rates were low, mostly below 2 events per 100.000 person-years. Rates increased 247 
with age-group. The highest overall incidence rate was noted for all-cause mortality, 248 
being 1.9 (95% CI 1.71 to 2.11) per 100.000 person-years for patients with type 1 249 
diabetes and 0.6 (95% CI 0.56 to 0.66) for corresponding controls. In the highest age-250 
group, incidence rates for CVD and CHD were 1.53 (95% CI 1.35 to 1.73) and 1.8 (95% 251 
CI 1.61 to 2.01) per 100.000 person-years, respectively, for patients, and 0.45 (95% CI 252 
0.41 to 0.5) 0.46 (95% CI 0.41 to 0.5) for controls. Corresponding rates for those who 253 
developed diabetes below 10 years of age were 0.48 (0.38, 0.58) and 0.5 (0.41, 0.61) 254 
per 100.000 person-years. 255 
 256 
Life years lost 257 
There were marked differences in life years lost. Refer to Figure 1 and Supplementary 258 
Tables 7 through 9.  Overall, being diagnosed with type 1 diabetes before 10 years of 259 
age resulted in loss of 16.0 (95% CI 15.7, 16.4) life-years. Men who were diagnosed 260 
before 10 years of age lost 14.2 (95% CI 14.4, 15.8) life-years. Females who were 261 
diagnosed at the same age lost 17.7 (95% CI 17.1, 17.8) life-years. Patients diagnosed 262 
after 20 years of age loss approximately 10 life-years. 263 
 264 
Hazard ratios for mortality and cardiovascular outcomes 265 
All following hazard ratios represent the risk in people with type 1 diabetes, 266 
according to age at diagnosis, compared with controls. Overall hazard ratios refer to 267 
estimates for men and women collectively. Sex-specific hazard ratios are also 268 
provided. 269 
 270 
General patterns 271 
Patients with diabetes displayed an excess risk of eight of nine outcomes, with atrial 272 
fibrillation being the only exception. There was a ubiquitous inverse association 273 
between age at diagnosis and risk of the outcomes. Excess risks were particularly 274 
pronounced in women; the greatest risks were noted for coronary artery disease and 275 
myocardial infarction, for which women with type 1 diabetes displayed a 60- and 90-276 
fold increased risk, respectively. 277 
 278 
Mortality 279 
Figure 2 presents overall hazard ratios (men and women collectively). Hazard ratios 280 
(95% CI) for all-cause mortality were as follows: 4.11 (3.24 − 5.22), 3.21 (2.58 − 4.00), 281 
3.02 (2.44 − 3.73), 2.90 (2.41 − 3.50) and 2.83 (2.38 − 3.37), going from the youngest 282 
age-group to the oldest. CV mortality displayed a similar trend. The lowest hazard 283 
ratio for CV mortality, noted for those with diabetes onset at age 26–30 years, was 284 
3.64 (2.34 − 5.66). The highest hazard ratio was 7.38 (3.65 − 14.94) and noted for 285 
those with disease onset at age 0–10 years. Excess risk of non-CV mortality was 286 
consistently elevated with an incremental increase (albeit less marked than for CVD) 287 
with youngers age at onset of T1D. Hazard ratio for patients diagnosed in the age 288 
range 26–30 years was 2.78 (2.29–3.38). For those diagnosed in the age-range 0–10 289 
years the hazard ratio was 3.96 (3.06–5.11). 290 
 291 
Figure 3 presents hazard ratios according to sex. There were no material differences 292 
between males and females (with type 1 diabetes) in the age-range 20 to 30 years. 293 
However, women displayed greater hazard ratios when developing diabetes before 294 
20 years of age. For those developing type 1 diabetes before 10 years of age, women 295 
displayed a 6-fold increased mortality risk, as compared with a 3-fold risk noted in 296 
males with type 1 diabetes. 297 
 298 
Cardiovascular outcomes 299 
Cardiovascular risks were considerably higher and strongly related to age at disease 300 
onset. Several strong associations were noted. 301 
 302 
Overall hazard ratio for CVD (Figure 2) for patients diagnosed in the age-range 26–30 303 
years was 3.85 (3.05–4.87), whereas patients diagnosed in the age-range 0–10 years 304 
displayed a hazard ratio of 11.44 (7.95–16.44). There were notable differences 305 
between males and females, such that the latter displayed greater excess risk 306 
throughout (Figure 3). Women who developed type 1 diabetes before 10 years of age 307 
had a 13-fold increased risk of CVD. 308 
 309 
Overall hazard ratio for CHD was 30.50 (19.98–46.57) for those diagnosed in the age-310 
range 0–10 years (Figure 2). The lowest hazard ratio for CHD was 6.08 (4.71–7.84), 311 
which was noted for those diagnosed in the age-range 26–30 years. There were 312 
differences between males and females with type 1 diabetes (Figure 3). Males with 313 
type 1 diabetes displayed a hazard ratio of 16.95 (10.03–28.67) and the 314 
corresponding figure for females was 58.73 (28.86–119.55). 315 
 316 
Overall hazard ratio for AMI was 30.95 (17.59–54.45) for those diagnosed in the age-317 
range 0–10 years (Figure 2). Women who developed type 1 diabetes before 10 years 318 
of age had a hazard ratio of 91.07 (32.72–253.47). The corresponding figure in males 319 
was 15.11 (7.53–30.33). These differences persisted further down the age span 320 
(Figure 3). The lowest hazard ratio for women with type 1 diabetes was 14.13 (7.75–321 
25.76), which was noted for those with disease onset between age 26–30 years. 322 
 323 
Overall hazard ratio for stroke was 6.45 (4.04–10.31) for disease onset between 0–10 324 
years of age (Figure 2). This excess risk declined gradually with increasing age at 325 
onset, such that those with disease onset between 26–30 years had a hazard ratio of 326 
3.22 (2.35–4.00). There were no significant differences between men and women 327 
with type 1 diabetes (Figure 3). 328 
 329 
Hazard ratios for heart failure differed by a factor of two across the age-span. The 330 
lowest hazard ratio was 5.07 (3.55–7.22) and noted for the age-group 26–30 years 331 
(Figure 2). Being diagnosed with type 1 diabetes in the age-range 0–10 years resulted 332 
in a hazard ratio of 12.90 (7.39–22.51). There were no material differences between 333 
men and women with type 1 diabetes (Figure 3). 334 
 335 
With regards to atrial fibrillation, we did not note any excess risk for patients with 336 
diabetes, except from males with disease onset between age 21–25 years.  337 
 338 
Causes of death in relation to age at diagnosis 339 
Circulatory and endocrine causes represented roughly 70% of all primary causes of 340 
death in those with disease onset at age 0–10 years (Figure 4). The corresponding 341 
figure for those with age 26–30 was 61%. Other causes, especially neoplasms, 342 
became more common with later onset T1D. 343 
 344 
Discussion 345 
In this nationwide study of patients with type 1 diabetes we show that age at disease 346 
onset is an important determinant of survival and cardiovascular disease. The 347 
differences in hazard related to age of disease onset were in many cases extreme. 348 
Patients with type 1 diabetes with disease onset before 10 years of age experienced a 349 
30-fold increased risk of CHD and AMI in their early adult years. Women with onset of 350 
type 1 diabetes before 10 years of age displayed a 60- and 90-fold increased risk of 351 
CHD and AMI, respectively, in the same early adult period. Onset of type 1 diabetes 352 
before 10 years of age was associated with 12-fold increased risk of heart failure over 353 
the same period and mortality risks, relative to age and sex matched controls, 354 
differed by 128%. It is important to note that although the relative risks were 355 
extremely high, absolute risks were low throughout. This is explained by the fact that 356 
we studied a relatively young cohort (mean age 29). However, our previous studies, 357 
in which the persons with T1D were approximately 8 years older than in the present 358 
study, we demonstrated that absolute risks were much higher.3 Hence, if the relation 359 
between age at diagnosis and excess risks persist further into the future, it would in 360 
time translate to a very high absolute risk, as corroborated by our analysis of loss of 361 
life years; women who developed type 1 diabetes before 10 years of age lost almost 362 
18 life-years. A diagnosis at 26-30 was associated with around 10 years loss. 363 
 364 
In the light of the fact that around half of type 1 diabetes cases are diagnosed before 365 
14 years of age,20 this study highlights a need to consider age at diagnosis in 366 
guidelines.  The magnitude of these risk estimates – with point estimates 367 
approaching 100 in the early adult years – appear at least as high as those conferred 368 
by familial hypercholesterolemia.21  369 
 370 
Our risk estimates for the 0-10 years of age of onset subgroup are higher than figures 371 
presented in the most recent statement from the American Heart Association and 372 
American Diabetes Association, which noted that patients with T1D were at 3– (men) 373 
and 7–fold (women) increased risk of CHD.  Notably, this statement did not consider 374 
age of onset as a risk stratifier, whereas our data suggest age of onset should now be 375 
considered in the management of CVD risk in T1DM. 376 
 377 
Our data suggests that excess risks are generally greater in women developing T1D 378 
(with the exception of heart failure). This can, to some extent, be explained by the 379 
fact that women in the general population have a low risk of these events, as 380 
compared with men. Hence, higher excess risks in women with type 1 diabetes do 381 
not necessarily translate into higher absolute risks compared to their male 382 
counterparts.22 383 
 384 
Our data add meaningfully to the limited information available on the long-term 385 
survival in type 1 diabetes in relation to age at disease onset. Conway and colleagues 386 
compared mortality in diabetes with onset in childhood (under 20 years of age, 387 
n=162) versus young adulthood (20 to 29, n=313); no marked differences in mortality 388 
or coronary artery disease were noted, although the small sample offered low 389 
power.14 In a bigger study, Harjutsalo and colleagues examined CHD mortality in early 390 
(0–14 years) and late onset (15–29) T1D. They reported that CHD mortality rate was 391 
2.8-fold greater in early onset type 1 diabetes compared with late onset type 1 392 
diabetes. Harjutsalo et al suggested that this higher risk may be explained by the 393 
longer duration of diabetes in those with early onset type 1 diabetes.  Our study, 394 
which had the benefits of individual’s controls, adjustment for duration, more age 395 
subgroups, as well as a range of CVD outcomes, demonstrates that mortality in T1D is 396 
uniformly and markedly elevated as compared with the general population. 397 
 398 
Although the explanations for our findings are likely to be multifaceted, diabetes 399 
duration is likely to play a key role, since even though we adjusted for duration more 400 
robustly than other studies, complete adjustment is near impossible. Duration of 401 
diabetes is a component of total glycemic load. The latter–defined as the 402 
vasculatures cumulative exposure to glucose–is a function of duration of diabetes 403 
and glycemic variability. The longer the duration of diabetes, the greater the glycemic 404 
load and thus the damages (analogous to area under the curve for exposure to LDL 405 
cholesterol).23,24 It is also clear from our data that the coronary arteries seem 406 
especially vulnerable to hyperglycemia, and more so when hyperglycaemia 407 
commences early in life (under 10-15 years). 408 
One possible recent explanation for our findings is that patients with a younger age 409 
of onset have a more severe and rapid loss of beta-cells which contributes to higher 410 
glycaemia, as we noted. Recent studies of the pancreas of patients who die close to 411 
diagnosis of diabetes show that those diagnosed under 7 years have very severe loss 412 
of residual insulin-containing islets (ICIs) compared to those diagnosed over the age 413 
of 13 years who retain ∼40% ICIs.25,26 A different type of insulitis is seen in these 2 414 
subgroups:  in those diagnosed under 7 there is a high proportion of CD20 B 415 
lymphocytes (CD20Hi), in contrast to those diagnosed over 13 years who have a low 416 
proportion (CD20Lo).25  This implies that the two forms of insulitis are differentially 417 
aggressive and that the patients diagnosed under 7 years with a CD20Hi profile lose 418 
their β-cells at a more rapid rate. 419 
Moreover, children and adolescents with type 1 diabetes exhibit subclinical CVD 420 
abnormalities already after 10 years diabetes duration. This has been demonstrated 421 
using numerous methodologies.27-31 422 
Our data suggest a need to better target cardiovascular risk in those with childhood 423 
onset type 1 diabetes. There are readily available and effective means to mitigate the 424 
risk of coronary events, notably statins, blood pressure lowering, insulin pump, 425 
continuous glucose measurement etc. Trial data suggest CVD reductions in type 1 426 
diabetes with statins are near identical in magnitude to those with type 2 diabetes,32 427 
whereas observational data suggest statin use markedly lower CVD risk in type 1 428 
diabetes.33-35 More recent trials evidence from adDIT trial support an effect of ACE 429 
inhibition to lessen microalbuminuria and statins to lower lipids when prescribed in 430 
adolescence, and to do so without any short term harm.36   431 
We are not advocating giving children with type 1 diabetes statins or ACE inhibitors 432 
but our data in conjunction with prior observations might argue for greater 433 
consideration of statins once individuals with early onset type 1 diabetes reach 30 to 434 
40 years of age.  From current data, plus prior work in Scotland,37 only around 10-435 
20% of individuals with type 1 diabetes appear to be on statin by 40 years of age, and 436 
more than half have SBP>120 mmHg.  Some guidelines include long duration of 437 
diabetes (i.e. >20 years) as a reason to consider statins in 30-40 year old patients with 438 
type 1 diabetes.38 However, that such patients - who would have been diagnosed 439 
when under 10 or 20 years of age - also have highest risks of AMI and lose most life 440 
years from their diabetes, is strongly advanced by our present findings. We believe 441 
physicians might need to reconsider more complete targeting of cholesterol, blood 442 
pressure and glycemia in their younger onset patients when they reach 30-40 years 443 
of age, if possible and as clinically indicated. We appreciate ACE inhibitors are 444 
teratogenic whereas, although yet no clear data for such risks, statins are also not 445 
recommended for women planning pregnancy. Thus, some caution in women with 446 
type 1 diabetes is needed but even so, better blood pressure control without ACE 447 
inhibitors in women, improved glycaemia control and smoking cessation in such 448 
groups could meaningfully extend life expectancy in those with younger onset 449 
diabetes.  Such interventions given earlier in life, increase life expectancy most,38 and 450 
some interventions (e.g. statins) have legacy effects.39  In other words, whilst short 451 
term risks are low to modest, given young age of diabetes onset, lifetime risks will be 452 
high and thus gains from preventative therapies will be greatest when given earlier in 453 
life. 454 
There are a number of limitations to the current study. The investigation is a register 455 
study, which has limitations related to such design and data. We lacked information 456 
on glycaemic control prior to enrolment in the registry. We used an epidemiological 457 
definition of type 1 diabetes, which implies that misclassification of diabetes type is 458 
possible. However, a validation study has demonstrated that the epidemiological 459 
classification is highly reliable.16 Furthermore, we excluded patients with diabetes 460 
duration above 20 years in order to compute reliable regression models; this slightly 461 
restricts the permitted inferences but it does not affect the reliability of the 462 
estimates. Neither did this affect calculation of life years lost, since those analyses 463 
included all patients (no restriction with regards to diabetes duration; i.e virtually all 464 
Swedes with type 1 diabetes). 465 
To conclude, independent of diabetes duration, age at onset of type 1 diabetes 466 
appears an important determinant of survival, as well as all cardiovascular outcomes. 467 
Early onset type 1 diabetes is associated with up to 30 times increased risk of serious 468 
cardiovascular outcomes, with risk levels being 90 times higher for women with early 469 
onset diabetes, who also die around 18 years earlier than their diabetes free 470 
counterparts. These findings advance the arguments for wider and earlier use of 471 
cardioprotective agents. 472 
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